Read More Pharma Industry News J&J’s Talvey combination cuts the risk of death by up to 53% in earlier-line multiple myeloma Johnson & Johnson (JNJ) Talvey combination cut the risk of death by up to 53% in earlier-line multiple myeloma, with FDA and EMA filings underway. Full analysis. bySrinathJune 15, 2026